Pharmacosmos wins Chinese reimbursement deal
The Chinese health agency, NHSA, has granted Pharmacosmos’s intravenous iron treatment, Monofor, national reimbursement in China – one of the largest iron deficiency markets in the world.
BY ULRICH QUISTGAARD, TRANSLATED BY KATRINE GØTHLER
Going forward, Pharmacosmos can look forward to receiving reimbursement on the Chinese market for sales of its intravenous (IV) drug against iron deficiency, Monofor.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pharmacosmos tight-lipped on competitor's Chinese market nod
For subscribers
China approves Vifor's iron deficiency IV infusion
For subscribers
